Syncom Formulations (India) Limited SYNCOMF NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.syncomformulations.com

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers its pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, liquids orals, and effervescent. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.

Market & Price

Market Cap

₹1,410.94 Cr

Current Price

₹15.01

High / Low (52W)

₹22.15 / ₹10.30

Beta

Valuation

Stock P/E

20.56

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹4.10

Price to Book

3.66

P/S

2.71

EV/EBITDA

12.04

Dividend Yield

Profitability & Returns

ROCE

18.71%

ROE

20.19%

ROA

13.49%

Profit Margin

14.69%

Op Margin

14.42%

EPS (Latest Qtr)

₹0.23

EPS (TTM)

₹0.73

Balance Sheet & Liquidity

Debt/Equity

0.35

Quick Ratio

2.15

Current Ratio

3.19

Debt

₹1.47 Cr

Total Assets

₹413.28 Cr

Current Assets

₹269.97 Cr

Working Capital

₹210.66 Cr

Ownership

Promoter Holding

50.57%

Chg in Prom Hold

FII / Inst Holding

0.13%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹1,288.13 Cr

Total Revenue (TTM)

₹520.51 Cr

EBITDA

₹106.98 Cr

Free Cash Flow

₹60.64 Cr

Operating Cash Flow

₹58.08 Cr

Shares Outstanding

₹94.00 Cr

Gross Margin

45.39%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

28.05%

Profit 5Y

35.68%

Revenue (YoY)

-9.00%

Earnings (YoY)

68.80%

PROS

Strong return on equity of 20.2%.
Compounding revenue at 28.1% over 5 years.
Profit CAGR of 35.7% over 5 years.
Generates positive free cash flow.

CONS

Trading 32.2% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SYNCOMF Syncom Formulations (India) Limited NSEPHARMA	15.01	20.56	₹1,410.94 Cr	-	18.71%	20.19%	28.05%	35.68%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Revenue	-	127.53 Cr	141.24 Cr	116.90 Cr	121.72 Cr	115.14 Cr
Cost of Revenue	-	86.66 Cr	108.46 Cr	69.17 Cr	70.75 Cr	61.04 Cr
Gross Profit	-	40.88 Cr	32.77 Cr	47.73 Cr	50.96 Cr	54.10 Cr
Operating Expenses	-	27.45 Cr	11.10 Cr	33.27 Cr	33.91 Cr	34.25 Cr
Operating Income	-	13.42 Cr	21.68 Cr	14.47 Cr	17.05 Cr	19.85 Cr
EBITDA	-	18.77 Cr	24.55 Cr	21.88 Cr	23.65 Cr	26.71 Cr
Interest Expense	-	19.82 L	-3.91 L	25.08 L	26.49 L	26.34 L
Pretax Income	-	17.26 Cr	23.30 Cr	20.29 Cr	22.04 Cr	25.09 Cr
Tax Provision	-	4.26 Cr	5.61 Cr	4.54 Cr	5.44 Cr	6.18 Cr
Net Income	-	13.00 Cr	17.69 Cr	15.75 Cr	16.60 Cr	18.91 Cr
Diluted EPS	0.16	0.14	-	0.21	0.18	0.23

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Revenue	217.82 Cr	222.49 Cr	259.24 Cr	457.37 Cr
Cost of Revenue	146.85 Cr	149.85 Cr	165.00 Cr	315.43 Cr
Gross Profit	70.97 Cr	72.64 Cr	94.24 Cr	141.94 Cr
Operating Expenses	53.70 Cr	56.18 Cr	69.07 Cr	87.79 Cr
Operating Income	17.27 Cr	16.45 Cr	25.17 Cr	54.15 Cr
EBITDA	31.95 Cr	34.30 Cr	43.03 Cr	71.42 Cr
Interest Expense	1.83 Cr	3.19 Cr	4.36 Cr	70.90 L
Pretax Income	26.18 Cr	26.57 Cr	33.95 Cr	65.51 Cr
Tax Provision	6.39 Cr	6.50 Cr	8.64 Cr	16.08 Cr
Net Income	19.79 Cr	20.07 Cr	25.31 Cr	49.43 Cr
Diluted EPS	0.24	0.22	0.27	0.53

Compounded Sales Growth

5 Years:	28.05%
1 Year:	-9.00%

Compounded Profit Growth

5 Years:	35.68%
1 Year:	68.80%

Stock Price Performance

1 Year:	-30.64%
6 Months:	-3.97%
3 Months:	+17.08%
1 Month:	+9.24%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Assets	308.24 Cr	377.83 Cr	404.66 Cr	413.28 Cr
Current Assets	139.80 Cr	181.69 Cr	274.78 Cr	269.97 Cr
Cash & Equivalents	21.61 L	75.81 L	63.29 Cr	65.85 L
Inventory	19.51 Cr	21.20 Cr	21.08 Cr	41.33 Cr
Receivables	67.55 Cr	75.51 Cr	103.30 Cr	107.55 Cr
Total Liabilities	86.02 Cr	121.82 Cr	116.52 Cr	71.12 Cr
Current Liabilities	78.26 Cr	113.16 Cr	106.52 Cr	59.31 Cr
Long Term Debt	0	-	-	-
Total Debt	57.79 Cr	83.18 Cr	72.49 Cr	4.58 Cr
Total Equity	222.22 Cr	256.01 Cr	288.14 Cr	342.16 Cr
Shares Outstanding	86.25 Cr	94.00 Cr	94.00 Cr	94.00 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Operating Cash Flow	16.33 Cr	10.53 Cr	-5.96 Cr	23.44 Cr
Investing Cash Flow	-27.07 Cr	-44.95 Cr	83.02 Cr	-18.20 Cr
Financing Cash Flow	8.29 Cr	35.00 Cr	-14.56 Cr	-67.90 Cr
Capital Expenditure	-11.31 Cr	-20.63 Cr	-8.14 Cr	-9.96 Cr
Free Cash Flow	5.02 Cr	-10.11 Cr	-14.09 Cr	13.48 Cr
Net Change in Cash	-2.45 Cr	57.80 L	62.50 Cr	-62.67 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Gross Margin %	32.6%	32.6%	36.4%	31.0%
Operating Margin %	7.9%	7.4%	9.7%	11.8%
Net Margin %	9.1%	9.0%	9.8%	10.8%
ROE %	8.9%	7.8%	8.8%	14.4%
ROCE %	7.5%	6.2%	8.4%	15.3%

Shareholding Pattern

Insiders

50.57%

Institutions

0.13%

Public Float

0.26%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SYNCOMF

No recent headlines available.

SYNCOMF · Healthcare